Prothena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by Analysts

Key Points

• Analyst consensus: "Hold" — 11 analysts rate Prothena with a consensus "Hold" (2 sell, 4 hold, 4 buy, 1 strong buy) and an average 1‑year price target of $21.67.
• Heavy institutional ownership — institutions own 97.08% of the stock, with notable stake increases by Rubric Capital (≈3.68M shares) and State Street (≈2.27M shares) in recent quarters.
• Unprofitable but slight EPS beat — shares opened at $9.52 (market cap ≈$512M); Prothena reported Q EPS of -$0.44 (vs. -$0.45 est.) but just $0.02M revenue and very negative net margins and ROE.

Prothena Corporation plc (NASDAQ:PRTA - Get Free Report) has been assigned a consensus rating of "Hold" from the eleven ratings firms that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $21.6667.

A number of research analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft set a $19.00 target price on shares of Prothena in a research note on Monday, December 1st. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Prothena in a report on Monday, December 29th. Stifel Nicolaus set a $19.00 price objective on Prothena in a report on Friday, March 13th. Citizens Jmp set a $19.00 target price on Prothena in a research report on Monday, December 1st. Finally, Royal Bank Of Canada boosted their target price on Prothena from $11.00 to $12.00 and gave the company a "sector perform" rating in a research note on Friday, February 20th.

Institutional Investors Weigh In On Prothena

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rubric Capital Management LP boosted its position in Prothena by 138.7% during the fourth quarter. Rubric Capital Management LP now owns 3,677,331 shares of the biotechnology company's stock worth $35,119,000 after purchasing an additional 2,136,958 shares during the period. State Street Corp raised its position in shares of Prothena by 151.7% in the fourth quarter. State Street Corp now owns 2,267,802 shares of the biotechnology company's stock valued at $21,658,000 after purchasing an additional 1,366,764 shares during the period. Rangeley Capital LLC purchased a new stake in shares of Prothena during the 2nd quarter valued at approximately $4,342,000. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Prothena during the 3rd quarter valued at approximately $6,386,000. Finally, Federated Hermes Inc. boosted its holdings in Prothena by 116.2% in the 2nd quarter. Federated Hermes Inc. now owns 1,181,087 shares of the biotechnology company's stock worth $7,169,000 after buying an additional 634,832 shares during the period. 97.08% of the stock is currently owned by institutional investors.

Prothena Price Performance

Shares of Prothena stock opened at $9.52 on Friday. The firm has a market cap of $512.46 million, a PE ratio of -2.10, a P/E/G ratio of 0.62 and a beta of -0.24. Prothena has a 1 year low of $4.32 and a 1 year high of $13.52. The stock has a fifty day moving average price of $9.16 and a 200-day moving average price of $9.56.

Prothena (NASDAQ:PRTA - Get Free Report) last posted its quarterly earnings results on Thursday, February 19th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.01. Prothena had a negative net margin of 2,520.57% and a negative return on equity of 65.89%. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.67 million. As a group, equities analysts anticipate that Prothena will post -4.04 EPS for the current fiscal year.

Prothena Company Profile

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.